NCT00139113 - Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children | Biotech Hunter

Enrollment

248

Participants

Timeline

Start Date

September 30, 1996

Primary Completion Date

June 30, 2001

Study Completion Date

June 30, 2001

Conditions

Hepatitis A

Interventions

BIOLOGICAL

hepatitis A vaccine

2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.

Trial Locations (2)

99501

Anchorage Neighborhood Health Center, Anchorage

99508

Alaska Native Medical Center, Anchorage